Anaptysbio, Inc.
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 17, 2027The maintenance fee for Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3) (US 10,508,149) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
- 1 fee due Jul 7, 2027The maintenance fee for Antibodies directed against interleukin 36 receptor (IL-36R) (US 10,526,410) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,738,117 | Antibodies Directed Against Programmed DEATH-1 (PD-1) In force · High confidence | In force | High confidence | |
| US 9,815,897 | Antibodies Directed Against Programmed DEATH-1 (PD-1) In force · High confidence | In force | High confidence | |
| US 10,526,410 | Antibodies directed against interleukin 36 receptor (IL-36R) In force · From the USPTO record | In force | From the USPTO record | |
| US 11,130,814 | Method of treating pustular psoriasis with antibodies directed against interleukin 36 receptor (IL-36R) In force · From the USPTO record | In force | From the USPTO record | |
| US 10,508,149 | Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3) In force · High confidence | In force | High confidence | |
| US 11,352,427 | Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3) In force · High confidence | In force | High confidence | |
| US 10,836,824 | Antibodies directed against lymphocyte activation gene 3 (LAG-3) In force · From the USPTO record | In force | From the USPTO record | |
| US 12,391,761 | Antibodies directed against interleukin 36 receptor (IL-36R) In force · From the USPTO record | In force | From the USPTO record | |
| US 12,715,924 | Method of Treating Ichthyosis in a Subject by Administering an Anti-Interleukin 36 Receptor (IL-36R) Binding Agent In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 14 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending · 5 abandoned · 12 no status recorded